血清甲状腺抗体在口腔扁平苔藓治疗方案选择中的意义初步研究
本研究纳入116例口腔扁平苔藓患者,比较甲状腺抗体阳性组与阴性组在不同治疗方案下的疗效。结果显示,局部治疗及联合免疫抑制剂对阴性组有效,对阳性组无统计学意义;联合免疫增强剂对两组均有效,且两组间无显著差异。甲状腺抗体TPOAb、TGAb可作为OLP治疗方案选择的参考因素。
要点
- OLP伴甲状腺抗体阳性患者,可优先选择局部治疗联合口服免疫增强剂。
- 局部治疗及联合免疫抑制剂对甲状腺抗体阴性组有效,对阳性组无统计学意义。
- 局部治疗联合免疫增强剂对两组均有效,且两组间疗效无显著差异。
核心结论
- 甲状腺抗体TPOAb、TGAb可作为OLP治疗方案选择的参考因素。
- OLP伴甲状腺抗体阳性患者,可优先选择局部治疗联合口服免疫增强剂的治疗方案。
研究设计与样本
- 纳入2020年2月至2024年6月于浙江大学医学院附属口腔医院口腔内科中心因OLP就诊且做过TPOAb和TGAb血清检测的患者。
- 将TPOAb和(或)TGAb阳性患者纳入抗体阳性组,TPOAb及TGAb均阴性患者纳入抗体阴性组。
- 根据治疗方案分为局部治疗组、局部治疗联合口服免疫抑制剂组、局部治疗联合口服免疫增强剂组。
- 分别于治疗后2周、1个月比较两组不同治疗方案的临床疗效,并分析疗效与年龄、性别、甲状腺抗体滴度的相关性。
主要发现
- 共纳入116例OLP患者,抗体阳性组38例(32.8%),抗体阴性组78例(67.2%)。
- 与治疗前相比,局部治疗以及局部治疗联合口服免疫抑制治疗后2周、1个月,抗体阴性组改良OLP评分和疼痛程度显著改善(均P<0.01),抗体阳性组虽有缓解趋势但差异均无统计学意义(均P>0.05)。
- 局部治疗联合口服免疫增强剂者,治疗后2周和1个月抗体阳性组和抗体阴性组改良OLP评分和疼痛程度与治疗前相比差异均有统计学意义(P<0.01),两组间疗效差异无统计学意义(P>0.05)。
- 多因素Logistic回归分析显示,三组疗效与年龄、性别、TPOAb滴度、TGAb滴度均无显著相关性(P>0.05)。
关键数值与推荐
- 甲状腺抗体阳性定义为TPOAb和(或)TGAb阳性,阴性定义为TPOAb及TGAb均阴性。
- 局部治疗及局部治疗联合口服免疫抑制剂:抗体阴性组治疗前后改良OLP评分和疼痛程度改善均P<0.01,抗体阳性组均P>0.05。
- 局部治疗联合口服免疫增强剂:两组治疗前后改良OLP评分和疼痛程度改善均P<0.01,两组间P>0.05。
- 三组疗效与年龄、性别、TPOAb滴度、TGAb滴度相关性均P>0.05。
临床怎么用
- 作者认为甲状腺抗体TPOAb、TGAb可作为OLP治疗方案选择的参考因素。
- 作者认为OLP伴甲状腺抗体阳性患者可优先选择局部治疗联合口服免疫增强剂的治疗方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the efficacy of different treatment of oral lichen planus (OLP) patients with thyroid antibody positive and its correlation with thyroid antibody, providing more targeted treatment for OLP patients with thyroid antibody positive. Methods: Patients who were admitted to Department of Oral Medicine, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine for OLP with serum thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TGAb) from February 2020 to June 2024 were included. Demographic and clinical data were recorded, and qualitative status and quantitative titers of TPOAb/TGAb were collected. TPOAb and/or TGAb positive patients were included into the thyroid antibody positive group, while patients with both TPOAb and TGAb negative were included into the thyroid antibody negative group. According to the treatment methods, they were divided into topical treatment group, topical treatment combined with oral immunosuppressant group, and topical treatment combined with oral immunoenhancer group. After 2 weeks and 1 month of treatment, the clinical efficacy of thyroid antibody positive group and negative group in OLP patients under different treatment methods were compared, and the correlations of different clinical efficacy with age, sex and thyroid antibody titer were analyzed. Results: A total of 116 OLP patients were included in this study, of which 38 (32.8%) were thyroid antibody positive and 78 (67.2%) were thyroid antibody negative. Compared with untreated, the modified OLP score and pain degree in thyroid antibody negative group were significantly improved after 2 weeks and 1 month of topical treatment and topical treatment combined with oral immunosuppression (P<0.01). Although the thyroid antibody positive group also showed a remission trend, there was no statistical significance before and after treatment (P>0.05). For topical treatment combined with oral immunoenhancer, the modified OLP score and pain degree in both groups of antibody positive and negative were statistically significant different after 2 weeks and 1 month of treatment compared with before (P<0.01), while there was no statistically significant difference between the two groups (P>0.05). Multivariate Logistic regression analysis showed that the treatment efficacy of OLP in topical treatment group, topical treatment combined with oral immunosuppressant group, and topical treatment combined with oral immunoenhancer group had no significant correlation with age, sex, as well as the TPOAb and TGAb titer (P>0.05). Conclusions: Thyroid antibody TPOAb and TGAb could be reference factors for the selection of OLP treatment plan. For patients of OLP with positive thyroid antibodies, topical therapy combined with oral immunoenhancers may be preferred. 目的: 初步探讨口腔扁平苔藓(OLP)伴甲状腺抗体阳性患者不同治疗方案的疗效及其与甲状腺抗体滴度的相关性,以期为伴甲状腺抗体阳性的OLP患者提供更有针对性的诊疗方案。 方法: 纳入2020年2月至2024年6月于浙江大学医学院附属口腔医院口腔内科中心因OLP就诊,且做过甲状腺过氧化物酶抗体(TPOAb)和甲状腺球蛋白抗体(TGAb)血清检测的患者。记录人口学资料及临床信息,收集患者TPOAb及TGAb的定性状况及其定量滴度。将TPOAb和(或)TGAb阳性患者纳入抗体阳性组,TPOAb及TGAb均阴性患者纳入抗体阴性组。根据治疗方案分为局部治疗组、局部治疗联合口服免疫抑制剂组、局部治疗联合口服免疫增强剂组。分别于治疗后2周、1个月比较抗体阳性组与抗体阴性组不同治疗方案的临床疗效,并分析不同临床疗效与年龄、性别、甲状腺抗体滴度的相关性。 结果: 本研究共纳入116例OLP患者,其中抗体阳性组患者38例(32.8%),抗体阴性组患者78例(67.2%)。与治疗前相比,局部治疗以及局部治疗联合口服免疫抑制治疗后2周、1个月,抗体阴性组患者的改良OLP评分和疼痛程度显著改善(均P<0.01),而抗体阳性组患者虽有缓解趋势,但治疗前后相比差异均无统计学意义(均P>0.05)。局部治疗联合口服免疫增强剂者,治疗后2周和1个月抗体阳性组和抗体阴性组患者改良OLP评分和疼痛程度与治疗前相比差异均有统计学意义(P<0.01),且两组间疗效差异无统计学意义(P>0.05)。多因素Logistic回归分析显示,OLP在局部治疗组、局部治疗联合口服免疫抑制剂组、局部治疗联合口服免疫增强剂组的疗效与年龄、性别、TPOAb滴度、TGAb滴度均无显著相关性(P>0.05)。 结论: 甲状腺抗体TPOAb、TGAb可作为OLP治疗方案选择的参考因素;OLP伴甲状腺抗体阳性患者,可优先选择局部治疗联合口服免疫增强剂的治疗方案。.
引用
- Liu CX, Chen FM, Zhang SS, et al. [Preliminary study on the significance of serum thyroid antibody in the selection of treatment for oral lichen planus]. Zhonghua Kou Qiang Yi Xue Za Zhi. 2025. PMID: 40015703. doi:10.3760/cma.j.cn112144-20241216-00487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。